These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17117162)

  • 21. Progress in Parkinson's disease-where do we stand?
    Toulouse A; Sullivan AM
    Prog Neurobiol; 2008 Aug; 85(4):376-92. PubMed ID: 18582530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Will stem cell biology generate new therapies for Parkinson's disease?
    McKay R; Kittappa R
    Neuron; 2008 Jun; 58(5):659-61. PubMed ID: 18549778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early diagnosis of Parkinson's disease and initiation of treatment.
    Weiner WJ
    Rev Neurol Dis; 2008; 5(2):46-53; quiz 54-5. PubMed ID: 18660736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cycrimine, a new drug in the treatment of Parkinson's disease & Parkinsonism].
    KAFER JP; POCH GF
    Prensa Med Argent; 1957 Apr; 44(14):1071-5. PubMed ID: 13477721
    [No Abstract]   [Full Text] [Related]  

  • 25. Psychosocial counseling in Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S160-2. PubMed ID: 12211156
    [No Abstract]   [Full Text] [Related]  

  • 26. Only specialists should diagnose Parkinson's disease.
    Mayor S
    BMJ; 2006 Jul; 333(7557):14. PubMed ID: 16809701
    [No Abstract]   [Full Text] [Related]  

  • 27. Overview of Parkinson's disease.
    Lew M
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):155S-160S. PubMed ID: 18041935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-completion of changes to prescribed medications in people with Parkinson's disease.
    Ng WT; Caslake R; Counsell CE
    Age Ageing; 2007 May; 36(3):333-6. PubMed ID: 17267451
    [No Abstract]   [Full Text] [Related]  

  • 29. What is deep brain stimulation for Parkinson's disease?
    J Pract Nurs; 2009; 59(2):14-5. PubMed ID: 19719000
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment options for non-motor symptoms in late-stage Parkinson's disease.
    Coelho M; Ferreira J; Rosa M; Sampaio C
    Expert Opin Pharmacother; 2008 Mar; 9(4):523-35. PubMed ID: 18312155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A new spasmolytic neo-octinum, in the treatment of Parkinson's syndrome].
    KELLER H
    Munch Med Wochenschr; 1957 Jan; 99(2):51-3. PubMed ID: 13400088
    [No Abstract]   [Full Text] [Related]  

  • 32. Physical therapy in Parkinson's disease: evolution and future challenges.
    Keus SH; Munneke M; Nijkrake MJ; Kwakkel G; Bloem BR
    Mov Disord; 2009 Jan; 24(1):1-14. PubMed ID: 18946880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson-related dementias.
    Boeve BF
    Neurol Clin; 2007 Aug; 25(3):761-81, vii. PubMed ID: 17659189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging restorative treatments for Parkinson's disease.
    Deierborg T; Soulet D; Roybon L; Hall V; Brundin P
    Prog Neurobiol; 2008 Aug; 85(4):407-32. PubMed ID: 18586376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulating pathological oscillatory activity in Parkinson's disease: What's the rhythm?
    Timmermann L; Fink GR
    Exp Neurol; 2009 Feb; 215(2):209-11. PubMed ID: 19041091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
    Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
    Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential applications of nanotechnologies to Parkinson's disease therapy.
    Linazasoro G;
    Parkinsonism Relat Disord; 2008; 14(5):383-92. PubMed ID: 18329315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical development of gene therapy for Parkinson's disease.
    Porras G; Bezard E
    Exp Neurol; 2008 Jan; 209(1):72-81. PubMed ID: 17904121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?
    Jankovic J
    Ann Neurol; 2008 Mar; 63(3):267-9. PubMed ID: 18383071
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy for Parkinson's disease: a developing therapeutic strategy.
    Bradbury J
    Drug Discov Today; 2005 Aug; 10(16):1075-6. PubMed ID: 16182188
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.